At a corporate-sponsored health summit in late September, Health Secretary Robert Kennedy Jr. declared artificial intelligence more knowledgeable than physicians — a statement that carries unusual weight when spoken by the official who oversees the agencies responsible for regulating those very systems. Vice President Vance and other senior officials joined him before an audience of technology investors and industry players with active regulatory interests before the federal government. The moment raises an enduring question about power: who shapes the rules, and in whose company are those rul
Kennedy Touts AI Over Doctors at Industry-Backed Health Summit
AI systems are better informed than doctors, the health secretary told an industry audience.
Mark
Why does it matter what Kennedy said at this particular conference? He's expressing a view about AI—isn't that just one official's opinion?
Mimi
Because Kennedy isn't just any official. He runs the Health and Human Services Department, which oversees the FDA. That agency decides whether AI medical tools get approved, what safety testing they need, how they're monitored. His belief that AI is "better informed" than doctors could directly shape those decisions.
Luke
But we should be careful here. Did Kennedy actually say AI is categorically better than doctors, or did he say it's better informed in certain contexts? The summary says he claimed AI is "better informed," but we don't have his exact words. That's an important distinction.
Mimi
Fair point. The source material is thin on what he actually said word-for-word. What we know is that he made a statement at an industry conference that positioned AI favorably relative to physician judgment.
Mark
And the conference itself—why is that a problem? Government officials speak at industry events all the time.
Luke
They do, but the sponsorship matters. These weren't neutral academic institutions. The companies sponsoring the summit have regulatory business before Kennedy's department. They're not just listening to his views—they're funding the platform where he expresses them.
Mimi
It creates an appearance issue at minimum. When the health secretary tells an audience of AI companies that AI is better than doctors, those companies benefit from that messaging. It could influence how their products are regulated.
Mark
So you're saying this could affect how quickly AI medical tools get approved?
Mimi
Potentially. If Kennedy believes AI outperforms human doctors, that belief could lower the bar for safety testing or accelerate approval timelines. We don't know yet, but his statement signals a direction.
Luke
And that's the real story—not what he said, but what it might mean for actual healthcare policy. The problem is we don't have enough detail about what he actually claimed or how the health department plans to act on it. We're reading tea leaves.
El Pulso
- Kennedy told an industry-backed crowd that AI systems are 'better informed' than doctors — not a cautious endorsement, but a declaration of replacement over assistance.
- The MAHA Summit's sponsor list read like a regulatory docket: companies with pending business before the very health agencies whose leaders were now speaking from the stage.
- The AI healthcare market is expanding at speed, pouring billions into diagnostic and treatment tools that have largely escaped rigorous independent safety testing.
- Kennedy's own department controls FDA approvals and AI medical device oversight, meaning his stated beliefs could directly accelerate approvals and soften safety requirements.
- The administration official who built his reputation opposing pharmaceutical regulatory capture arrived at a conference that mirrored the very dynamic he has long condemned.
At a corporate-sponsored health summit in late September, Health Secretary Robert Kennedy Jr. declared artificial intelligence more knowledgeable than physicians — a statement that carries unusual weight when spoken by the official who oversees the agencies responsible for regulating those very systems. Vice President Vance and other senior officials joined him before an audience of technology investors and industry players with active regulatory interests before the federal government. The moment raises an enduring question about power: who shapes the rules, and in whose company are those rules imagined?
Health Secretary Robert Kennedy Jr. addressed the MAHA Summit in late September alongside Vice President JD Vance and other senior officials, telling an audience of corporate executives, venture capitalists, and technology entrepreneurs that artificial intelligence systems are better informed than doctors. The conference was sponsored by companies with direct regulatory business before federal agencies — including AI firms themselves.
The claim was not a modest one. Kennedy framed AI not as a tool to support physicians but as a superior replacement for their judgment, a distinction with real consequences at a moment when AI healthcare tools are proliferating rapidly and government oversight of them remains thin. Most diagnostic algorithms and clinical decision-support systems entering the market have not been subjected to rigorous independent testing.
The setting amplified the stakes. Kennedy's department oversees the FDA and sets policy for how AI medical tools are evaluated. If the health secretary believes machines outperform doctors, that conviction could shape approval timelines, safety thresholds, and the deference his agency extends to industry performance claims — all while billions in investment continue flowing into the sector.
The presence of top government officials at an industry-sponsored event drew immediate scrutiny. The companies in the room were not neutral observers; they were stakeholders whose regulatory futures depend in part on the officials addressing them. Kennedy has long positioned himself as a critic of pharmaceutical industry influence over health regulators — yet the scene at the MAHA Summit presented its own version of the entanglement he has spent years decrying.
Health Secretary Robert Kennedy Jr. stood before an audience of corporate executives, venture capitalists, and technology entrepreneurs at the MAHA Summit in late September and made a striking claim: artificial intelligence systems, he said, are better informed than doctors. Vice President JD Vance joined Kennedy and other senior government officials at the conference, which was sponsored by a roster of corporations with direct business interests pending before federal agencies—including AI companies themselves.
The setting mattered as much as the message. The MAHA Summit, which stands for Make America Healthy Again, drew attendees from the technology sector, pharmaceutical companies, and other industries with regulatory stakes in the health department's decisions. Kennedy's endorsement of AI superiority over medical professionals, delivered to this audience, represented a significant statement from the nation's top health official at a moment when artificial intelligence is reshaping medicine and when regulatory oversight of these systems remains sparse.
Kennedy's framing positioned AI not as a tool to assist physicians but as a replacement for their judgment—a distinction that carries weight in how healthcare policy might evolve. The claim that machines are "better informed" than the doctors who have spent years in medical training and practice reflects a particular view of expertise and knowledge. It also arrives at a time when AI companies are racing to develop diagnostic and treatment-recommendation systems with minimal government scrutiny, and when questions about the safety and accuracy of these tools remain largely unanswered.
The presence of Vice President Vance and other top officials at a conference sponsored by companies with regulatory business before the government raised immediate questions about the appearance of conflicts of interest. When government officials address industry-sponsored events, the dynamics shift: attendees are not neutral observers but stakeholders with financial and regulatory interests in the decisions those officials make. The companies sponsoring the summit were not passive hosts but active participants in an ecosystem where their regulatory fates depend partly on the officials now speaking from the stage.
Kennedy's health department oversees the FDA, which approves medical devices and drugs, and sets policy for how AI systems used in healthcare are evaluated and monitored. His statement that artificial intelligence outperforms human doctors could influence how his agency approaches the regulation of AI medical tools—whether it accelerates approvals, loosens safety requirements, or defers to industry claims about performance. The timing is significant: the AI healthcare market is expanding rapidly, with billions in investment flowing into startups developing diagnostic algorithms, treatment planners, and clinical decision-support systems. Most of these tools have not undergone rigorous independent testing.
The MAHA Summit itself reflects a broader shift in how health policy is being shaped during this administration. The conference brought together officials, industry players, and advocates for alternative medicine and skepticism toward conventional pharmaceutical approaches. Kennedy, who has long promoted vaccine skepticism and alternative health theories, has positioned his health department as a counterweight to what he views as regulatory capture by pharmaceutical companies. Yet the scene at the MAHA Summit—with government officials addressing an industry-sponsored gathering of companies with regulatory interests—presented its own version of the same dynamic he has criticized.
What Kennedy said about AI and doctors will likely echo through healthcare policy decisions in the months ahead. If the health secretary believes AI is superior to physician judgment, that belief could shape how his department evaluates AI medical tools, how quickly it approves them, and what safety standards it requires. For patients, doctors, and the companies developing these systems, Kennedy's words at the MAHA Summit signal a direction: toward greater reliance on algorithmic decision-making and less deference to medical expertise as traditionally understood.
Citas Notables
Kennedy stated that artificial intelligence systems are better informed than doctors— Health Secretary Robert Kennedy Jr., at the MAHA Summit
Quieres la nota completa?
Lee el original en The New York Times ↗
Politics & Governance